Symptomatic therapy

PreclinicalSmall molecule

UUniversity Medical Centre Ljubljana

Symptomatic therapy is one of 10 small molecule programs targeting Encephalitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EncephalitisActive, not recruiting

EncephalitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Encephalitis

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Decadron

AAspen Global Incorporated

Approved

2 3

Acanya

Pfizer

Preclinical

2 4

Opdivo

Bristol-Myers Squibb

Preclinical

1 5

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 6

Wellcovorin

EEastern Cooperative Oncology Group

Preclinical

2 7

ART5803

AArialys Therapeutics

Phase 2

1 8

Zovirax

BBp Consulting, Inc

Preclinical

1 9

Calculus Bovis Sativus

TTongji Hospital

Preclinical

1 10

Symptomatic therapy

UUniversity Medical Centre Ljubljana

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Encephalitis

NCT03956446

Clinical

Trials by Indication[1]

Encephalitis3 trials

Aseptic Meningoencephalitis in Slovenia

Unknown status·UUniversity Medical Centre Ljubljana··NCT02328469·800 enrolled

Tick-borne Encephalitis and Positive Borrelial Antibodies

Unknown status·UUniversity Medical Centre Ljubljana·N/A·NCT02463942·100 enrolled

Tick-borne Encephalitis and Borrelial Antibodies in Serum

Recruiting·UUniversity Medical Centre Ljubljana·N/A·NCT03956446·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Symptomatic therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Symptomatic therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Symptomatic therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Medical Centre Ljubljana company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Medical Centre Ljubljana

Symptomatic therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Encephalitis3 trials

References

Drug Info

Quick Facts

Related News